BMY Bristol-Myers Squibb Co

Bristol-Myers Squibb is a global biopharmaceutical company focused on oncology, cardiovascular disease, and immunology, with a robust drug pipeline. Sector: Healthcare.

Bristol-Myers Squibb Co (BMY) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

From a capital efficiency perspective, ROIC is 17.02%, WACC is 5.09%, and the economic spread is 11.93%. On balance, the company generate meaningful returns above their cost of capital, a hallmark of competitively advantaged businesses. Supporting metrics show ROE at 40.22% and ROA at 8.93%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company with credible compounding capacity if current operating execution persists.

Turning to how the market is pricing the underlying earnings, trailing P/E of 17.25, forward P/E of 9.51, PEG of 2.50. A moderate trailing-to-forward spread implies earnings growth is anticipated, though the scale of expected improvement is not dramatic. A PEG in this range suggests valuation is fair rather than compelling — the company is priced adequately for its growth, with limited buffer for downside revisions. At 1.26, the aggregate current ratio reflects the company with limited near-term liquidity buffer. The combined picture across P/E, forward P/E, PEG, and current ratio suggests a company that is priced for continued execution — where disappointment would be costly and outperformance would likely require positive earnings surprises.

On the margin front: gross margin sits at 71.85%, operating margin at 29.84%, and free cash flow margin at 26.65%. At this gross margin level, the company demonstrates significant pricing power and production efficiency. Operating margins sit in a healthy range — not exceptional, but indicating reasonable operational efficiency. At this FCF margin level, the company have considerable financial flexibility without reliance on external financing. This margin set supports the view that earnings quality is high and cash generation is not merely accounting-driven.

The two main inputs to the near-term picture — TTM revenue growth of 1.30% indicating muted but still positive top-line momentum across the company. Consensus EPS estimates point to 81.5% earnings growth over the next 12 months — a compelling near-term earnings catalyst that, if delivered, changes the valuation conversation materially. Analyst price targets suggest the target set points to a fairly constrained upside profile on a 12-month view. Revenue momentum establishes the baseline; analyst price targets reveal how much the market is already paying for future execution on top of that baseline. Delivered returns will ultimately be shaped by the gap — or lack thereof — between operating execution and the expectations embedded in current prices. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

The composite picture leans positive, with capital efficiency and growth momentum providing the core of the investment thesis.

This assessment is based solely on the quantitative metrics presented above and does not constitute financial advice. Investors should consider their own risk tolerance and conduct independent research before making investment decisions.